Ophthalmology Therapeutics Market in Asia-Pacific to 2019 - High Unmet Need and Moderate Short Term Prospects Focus Attention on Early Stage Activity

Ophthalmology Therapeutics Market in Asia-Pacific to 2019 - High Unmet Need and Moderate Short Term Prospects Focus Attention on Early Stage Activity

Summary

GBI Research has released its research, "Ophthalmology Therapeutics Market in Asia-Pacific to 2019 - High Unmet Need and Moderate Short Term Prospects Focus Attention on Early Stage Activity", which provides insights into two therapeutic indications in ophthalmology in Asia-Pacific (APAC) markets of India, China, Japan and Australia. The report provides an in-depth analysis of the therapeutic indications of ophthalmology, namely glaucoma and Dry Eye Syndrome (DES). The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis for these two ophthalmology indications.

Scope

- Disease overview and treatment usage patterns
- Market size and forecast for glaucoma and DES in APAC market from 2012 to 2019
- Major marketed products for the indications types covered
- In-depth pipeline analysis for glaucoma and DES
- Key drivers and restraints that have had and are expected to have a significant impact upon the market
- Key licensing and co-development agreements in the ophthalmology market

Reasons to buy

The report will enhance your decision-making capability by allowing you to -
- Align your product portfolio to the markets with high growth potential
- Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
- Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the ophthalmology market
- Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8
2 Ophthalmology Therapeutics Market in Asia-Pacific – Introduction 9
2.1 Dry Eye Syndrome 9
2.1.1 Classification 9
2.1.2 Symptoms 9
2.1.3 Etiology 9
2.1.4 Pathophysiology 10
2.1.5 Diagnosis 11
2.1.6 Epidemiology 12
2.1.7 Prognosis 13
2.1.8 Treatment Options 13
2.2 Glaucoma 14
2.2.1 Classification 14
2.2.2 Symptoms 15
2.2.3 Etiology 15
2.2.4 Pathophysiology 16
2.2.5 Diagnosis 17
2.2.6 Epidemiology 18
2.2.7 Prognosis 18
2.2.8 Treatment Options 19
3 Ophthalmology Therapeutics Market in Asia-Pacific – Marketed Products (Global) 20
3.1 Dry Eye Syndrome 20
3.2 Glaucoma 20
3.3 Key Marketed Products 21
3.3.1 Restasis 21
3.3.2 Systane 22
3.3.3 Diquas 23
3.3.4 Mucosta 24
3.3.5 Hyalein 25
3.3.6 Lumigan 26
3.3.7 Alphagan/Alphagan P 27
4 Ophthalmology Therapeutics Market in Asia-Pacific – Pipeline Analysis 28
4.1 Dry Eye Syndrome Pipeline 28
4.1.1 Overall Pipeline 28
4.1.2 Pipeline Analysis by Molecule Type 30
4.1.3 Pipeline Analysis by Mechanism of Action 31
4.2 Glaucoma Pipeline 33
4.2.1 Overall Pipeline 33
4.2.2 Pipeline Analysis by Molecule Type 34
4.2.3 Pipeline Analysis by Mechanism of Action 35
4.3 Promising Drug Candidates in the Pipeline 37
4.3.1 CF-101 37
4.3.2 MIM-D3 37
4.3.3 SAR-1118 37
4.3.4 DE-111 38
5 Ophthalmology Therapeutics Market in Asia-Pacific – Market Forecast to 2018 39
5.1 APAC Market 39
5.1.1 Treatment Usage Patterns 39
5.1.2 Annual Cost of Therapy 39
5.1.3 Market Size 39
5.2 India 41
5.2.1 Treatment Usage Patterns 41
5.2.2 Annual Cost of Therapy 41
5.2.3 Market Size 41
5.3 Australia 43
5.3.1 Treatment Usage Patterns 43
5.3.2 Annual Cost of Therapy 43
5.3.3 Market Size 43
5.4 China 45
5.4.1 Treatment Usage Patterns 45
5.4.2 Annual Cost of Therapy 45
5.4.3 Market Size 45
5.5 Japan 47
5.5.1 Treatment Usage Patterns 47
5.5.2 Annual Cost of Therapy 47
5.5.3 Market Size 47
5.6 Drivers and Barriers 49
5.6.1 Drivers 49
5.6.2 Barriers 50
6 Ophthalmology Therapeutics Market in Asia-Pacific – Deals and Strategic Consolidations (Global) 51
6.1 Deals Analysis 51
6.2 Major Co-Development Deals 52
6.2.1 NicOx Signs Research Agreement with Pfizer 53
6.2.2 Acucela Enters into Co-Development Agreement with Otsuka Pharma for Rebamipide 53
6.2.3 Akorn Enters into Agreement with Azad Pharma 53
6.3 Major Licensing Deals 54
6.3.1 NicOx Enters into Worldwide Licensing Agreement with Bausch & Lomb 55
6.3.2 Quark Pharma Amends Licensing Agreement with Pfizer for PF-655 55
6.3.3 Asterand Enters into Licensing Agreement with Allergan 55
7 Ophthalmology Therapeutics Market in Asia-Pacific – Appendix 56
7.1 All Pipeline Drugs by Phase 56
7.1.1 Discovery 56
7.1.2 Preclinical 56
7.1.3 IND/CTA-filed 58
7.1.4 Phase I 58
7.1.5 Phase II 59
7.1.6 Phase III 60
7.1.7 Pre-registration 60
7.1.8 Undisclosed 61
7.2 Market Forecasts to 2019 61
7.2.1 APAC 61
7.2.2 Australia 62
7.2.3 China 62
7.2.4 India 63
7.2.5 Japan 64
7.3 Market Definitions 64
7.4 Abbreviations 64
7.5 Sources 66
7.6 Research Methodology 67
7.6.1 Coverage 67
7.6.2 Secondary Research 68
7.6.3 Primary Research 68
7.6.4 Therapeutic Landscape 69
7.6.5 Geographical Landscape 71
7.6.6 Pipeline Analysis 71
7.7 Expert Panel Validation 71
7.8 Contact Us 71
7.9 Disclaimer 72

1.1 List of Tables
Table 1: Ophthalmology Therapeutics Market, Categories of Dry Eye Treatment, 2011 13
Table 2: Ophthalmology Therapeutics Market, Treatment Recommendations for Dry Eye Syndrome by Disease Severity Level, 2011 14
Table 3: Ophthalmology Therapeutics Market, Medicines for Lowering Eye Pressure, 2013 19
Table 4: Ophthalmology Therapeutics Market, Global, Pipeline (Discovery), 2013 56
Table 5: Ophthalmology Therapeutics Market, Global, Pipeline (Preclinical), 2013 56
Table 6: Ophthalmology Therapeutics Market, Global, Pipeline (IND/CTA-filed), 2013 58
Table 7: Ophthalmology Therapeutics Market, Global, Pipeline (Phase I), 2013 58
Table 8: Ophthalmology Therapeutics Market, Global, Pipeline (Phase II), 2013 59
Table 9: Ophthalmology Therapeutics Market, Global, Pipeline (Phase III), 2013 60
Table 10: Ophthalmology Therapeutics Market, Global, Pipeline (Pre-registration), 2013 60
Table 11: Ophthalmology Therapeutics Market, Global, Pipeline (Undisclosed), 2012 61
Table 12: Ophthalmology Therapeutics Market APAC, Dry Eye Syndrome, Market Forecast, 2012–2019 61
Table 13: Ophthalmology Therapeutics Market, APAC, Glaucoma, Market Forecast, 2012–2019 61
Table 14: Ophthalmology Therapeutics Market, Australia, Dry Eye Syndrome, Market Forecast, 2012–2019 62
Table 15: Ophthalmology Therapeutics Market, Australia, Glaucoma, Market Forecast, 2012–2019 62
Table 16: Ophthalmology Therapeutics Market, China, Dry Eye Syndrome, Market Forecast, 2012–2019 62
Table 17: Ophthalmology Therapeutics Market, China, Glaucoma, Market Forecast, 2012–2019 63
Table 18: Ophthalmology Therapeutics Market, India, Dry Eye Syndrome, Market Forecast, 2012–2019 63
Table 19: Ophthalmology Therapeutics Market, India, Glaucoma, Market Forecast, 2012–2019 63
Table 20: Ophthalmology Therapeutics Market, Japan, Dry Eye Syndrome, Market Forecast, 2012–2019 64
Table 21: Ophthalmology Therapeutics Market, Japan, Glaucoma, Market Forecast, 2012–2019 64

1.2 List of Figures
Figure 1: Ophthalmology Therapeutics Market, Global, Sales of Restasis ($m), 2006–2012 21
Figure 2: Ophthalmology Therapeutics Market, Global, Sales of Diquas ($m), 2010–2012 23
Figure 3: Ophthalmology Therapeutics Market, Global, Sales of Mucosta ($m), 2009–2012 24
Figure 4: Ophthalmology Therapeutics Market, Global, Sales of Hyalein ($m), 2009–2012 25
Figure 5: Ophthalmology Therapeutics Market, Global, Sales of Lumigan ($m), 2006–2012 26
Figure 6: Ophthalmology Therapeutics Market, Global, Sales of Alphagan/Alphagan P ($m), 2006–2012 27
Figure 7: Ophthalmology Therapeutics Market, Global, Dry Eye Syndrome, Pipeline (%), 2013 29
Figure 8: Ophthalmology Therapeutics Market, Global, Dry Eye Syndrome, Pipeline by Molecule Type, 2013 30
Figure 9: Ophthalmology Therapeutics Market, Global, Dry Eye Syndrome, Pipeline by Mechanism of Action, 2012 32
Figure 10: Ophthalmology Therapeutics Market, Global, Glaucoma, Pipeline, 2013 33
Figure 11: Ophthalmology Therapeutics Market, Global, Glaucoma, Pipeline by Molecule Type, 2013 34
Figure 12: Ophthalmology Therapeutics Market, Global, Glaucoma, Pipeline by Mechanism of Action, 2013 36
Figure 13: Ophthalmology Therapeutics Market, APAC, Market Size ($m), 2012–2019 40
Figure 14: Ophthalmology Therapeutics Market, India, Market Size ($m), 2012–2019 42
Figure 15: Ophthalmology Therapeutics Market, Australia, Market Size ($m), 2012–2019 44
Figure 16: Ophthalmology Therapeutics Market, China, Market Size ($m), 2012–2019 46
Figure 17: Ophthalmology Therapeutics Market, Japan, Market Size ($m), 2012–2019 48
Figure 18: Ophthalmology Therapeutics Market, Global, Deals, 2006–2013 51
Figure 19: Ophthalmology Therapeutics Market, Global, Co-Development Deals, 2006–2013 52
Figure 20: Ophthalmology Therapeutics Market, Global, Licensing Deals, 2006–2013 54
Figure 21: GBI Research Market Forecasting Model 70